Abstract 1035 Deciphering the early events molecular effectors and signaling pathways of the Anti-CD19 CAR-T cell therapy using Phosphoproteomics analysis
Introduction: A pioneer in the field of cell immunotherapy is the chimeric antigen receptor T-cell (CAR-T) therapy which utilizes genetically modified T-lymphocyte cells expressing receptors against certain targets on tumor cells, including CD-19, to induce cytotoxicity and the death of malignant cells. We generated an Anti-CD19 CAR-Jurkat, a T cell line, using a locally produced second-generation CAR-CD19 construct. This cell line allowed us to analyze early phosphoproteomic changes that are crucial for comprehending the signaling pathways and mechanism of action of this CAR.
Authors
- Raja Nirujogi
- John Oluwafemi Teibo (ORCID: https://orcid.org/0000-0002-0833-4828)
- Virgínia Picanço‐Castro (ORCID: https://orcid.org/0000-0001-8474-4610)
- Vítor M. Faça (ORCID: https://orcid.org/0000-0003-3205-7944)
- Dario R. Alessi (ORCID: https://orcid.org/0000-0002-2140-9185)
- Roberta Maraninchi Silveira (ORCID: https://orcid.org/0000-0002-7745-7274)
- L Souza (ORCID: https://orcid.org/0000-0002-3583-0907)
- Virgínia Campos Silvestrini (ORCID: https://orcid.org/0000-0003-4377-6469)
- Izadora Archiolli
Institutions
- Weizmann Institute of Science (IL)
Publication Details
- Journal
- Journal of Biological Chemistry
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jbc.2025.109803
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Minerva Foundation
- Weizmann Institute of Science